About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. Main lines of research:
IP: Pere Soler Palacín
To characterize the epidemiology of multiple sclerosis (MS) in Catalonia, a prospective registry of new cases of MS in Catalonia was set up in 2009 with the participation of 21 hospitals throughout Catalonia. Prevalence and incidence studies based on this population-based registry are being performed.
Recently, and in collaboration with the Center of Multiple Sclerosis of Catalonia (Cemcat), we have set up a prospective registry of vaccination in patients with Immuno-Mediated Inflammatory Disease (IMID) who are candidates for biological treatment with the aim of evaluating vaccine immunogenicity and safety that will allow establishing the best vaccination strategy. In addition, we will study the prevalence and impact of comorbidity on Multiple Sclerosis prognosis.
IP: Susana Otero Romero
Includes the evaluation of risk factors, features, evolution, host, and impact of these infections. The group has been pioneer in the organization of a national prevalence surveillance project for nosocomial infections (EPINE) that is underway since 1990, allowing the analysis and monitoring of this data for investigational purposes. We are currently working in a multilevel analysis to evaluate the characteristics associated with nosocomial infections due to antibiotic resistant microorganisms, based on data of EPINE study (PI15/00787). We are also involved in the national study of device-related infections in intensive care units (ENVIN-Helics).
IP: Jose Angel Rodrigo Pendás
The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.
The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
